Treatment of idiopathic pulmonary fibrosis with colchicine;Tratamiento de la fibrosis pulmonar idiopática con colchicina

Revista Medica de Chile

Volumn 126, Issue 11, 1998, Pages 1345-1353

  Undurraga P, Alvaro ^a   Meneses C, Manuel ^b   Sabbagh P, Eduardo ^b   Oyarzún G, Manuel ^b  

^a INSTITUTO NACIONAL DEL TÓRAX   (Chile)

^b NONE

Author keywords

Colchicine; Pulmonary fibrosis; Pulmonary gas exchange; Vital capacity

Indexed keywords

ANTIGOUT AGENT; COLCHICINE;

AGED; ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; LUNG FIBROSIS; LUNG GAS EXCHANGE; MALE; MIDDLE AGED; SPIROMETRY; VITAL CAPACITY;

AGED; AGED, 80 AND OVER; COLCHICINE; FEMALE; GOUT SUPPRESSANTS; HUMANS; MALE; MIDDLE AGED; PULMONARY FIBROSIS; PULMONARY GAS EXCHANGE; SPIROMETRY; VITAL CAPACITY;

EID: 3242825791     PISSN: 00349887     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. INSEL PA. Analgesic-antipyretic and antiinflammatory agents and drugs employed in the treatment of gout. En: Herdman JG & Limbird LE Eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics 9th Edition New York, Mc Graw-Hill, 1996; 647-9.
2. RENNARD S, BITTERMAN P, OZAKI T, ROM W, CRYSTAL R. Colchicine supresses the release of Fibroblast Growth Factors from Alveolar Macrophages in vitro. Am Rev Respir Dis 1988; 137: 181-5.
3. PINTO R, BORDONES J, AGUILAR M, CAPETILLO M, LATHROP ME, MENDOZA R, OYARZÚN MJ. Efecto de Colchicina en Fibrosis experimental en ratas. Rev Chil Enf Respir 1994, 10: 299.
4. PINTO RA, CAPETILLO M, LATHROP ME, MENDOZA R, OYARZÚN MJ. Colchicine does not revert the experimental lung fibrosis secondary to hyperoxia and paraquat. Am J Respir Crit Care Med 1997; 155: A320.
5. PETERS SG, MCDOUGALL JC, DOUGLAS WW, COLES DT, DE REMEE RA. Colchicine in the treatment of pulmonary fibrosis. Chest 1993; 103: 101-4.
6. HUNNINGHAKE G, KALICA A. Approaches to the treatment of pulmonary fibrosis. Am J Resp Crit Care Med 1995; 151: 915-8
7. UNDURRAGA A, SOLER T. Morbimortalidad en 20 pacientes portadores de Fibrosis Pulmonar Idiopática tratados con corticoides. Rev Chil Enf Resp 1993; 9; 230.
8. TURNER-WARWICK M, HASLAM PL. Antibodies in some chronic fibrosing lung diseases. I. Non organ-specific autoantibodies. Clin Allergy 1971; 1: 83-95
9. KATZENSTEIN AL, REYES JL, MAZUK MT. Acute interstitial pneumonia: a clinicopathologic, ultrastructural and cell kinetic study. Am J Surg Pathol 1986; 10: 256-7.
10. WATTERS LC, KING TE, SCHWARZ MI, WALDRON JA, STANFORD RE, CHERNIACK RM. A Clinical, radiographic and physiologic scoring system for the longitudinal assessment of patients with Idiopathic Pulmonary Fibrosis. Am Rev Respir Dis 1986; 133: 97-103.
11. AGUSTI C, XAUBET A, AGUSTI AG, ROCA J, RAMÍREZ J, RODRÍGUEZ-ROISIN R. Clinical and functional assessment of patients with idiopathic pulmonary fibrosis: results of a 3 years follow-up. Eur Resp J 1994, 7: 643-50.
12. WELLS AU, HANSSELL DM, RUBEENS MB, CULLINAN P, BLACK CM, DU BOIS RM. The predictive value of appearances on thin-sections computed tomography in fibrosing alveolitis. Am Rev Respir Dis 1993; 148 (4Pt1): 1076-82.
13. CHAN-YEUNG M, MÜLLER NL. Cryptogenic fibrosing alveolitis. Lancet 1997; 350: 651-6.
14. JOHNSTON I, PRESCOTT RJ, CHALMERS JC, RUDD RM. British Thoracic Society study of cryptogenic fibrosing alveolitis: current presentation and initial management. Thorax 1997; 52: 38-44.
15. MEIEH-SYDOM J, WEISS S, BUHL R, RUST M, RAGHU G. Idiopatic pulmonary fibrosis: current clinical concepts and challenges in management. Semi-nars Respir Crit Care Med 1994; 15: 77-96.
16. DOUGLAS WW, RYU JH, BJORAKER JA, SCHROEDER DR, MYERS JL, TALEZAAR HD, SWENSEN SJ, SCANLON PD, PETERS SG, DEREMEE RA. Colchicine versus prednisone as treatment of usual interstitial pneumonia. Mayo Clin Proc 1997, 72: 201-9.
17. CARRINGTON CB, GAENSLER EA, COUTU RE, FITZGERALD MX, GUPTA RG. Natural history and treated course of usual and desquamative interstitial pneumonia. N Engl J Med. 1978, 298: 801-9.